10x Genomics (TXG) Cost of Revenue (2018 - 2026)

10x Genomics' Cost of Revenue history runs 9 years deep, the most recent figure standing at $44.7 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 9.65% year-over-year to $44.7 million; the TTM figure through Mar 2026 stood at $194.2 million (down 1.76% YoY), while the FY2025 annual figure was $198.9 million, up 1.34% from the prior year.
• Cost of Revenue came in at $44.7 million for Q1 2026 at 10x Genomics, down from $53.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $68.2 million in Q4 2023 to a low of $25.5 million in Q1 2022.
• A 5-year average of $45.3 million and a median of $47.8 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 463.66% in 2022 and decreased 22.12% in 2024, its largest moves.
• 10x Genomics' Cost of Revenue stood at $36.8 million in 2022, then jumped by 85.18% to $68.2 million in 2023, then dropped by 20.72% to $54.1 million in 2024, then decreased by 2.0% to $53.0 million in 2025, then declined by 15.7% to $44.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $44.7 million, $53.0 million, and $48.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison